BioCentury | Oct 21, 2020
Product Development

UCSF’s virus-host protein interaction maps ID targets for COVID-19, future coronaviruses

A UCSF-led team has identified host pathways that could inform development of countermeasures against future coronaviruses, as they interact with multiple coronaviruses that recently made the leap...
BioCentury | Mar 25, 2020
Product Development

Repurposing candidates for COVID-19 from UCSF, Aldeyra

A UCSF team has keyed in on more than five dozen compounds against nearly as many targets that could be repurposed to target the virus behind COVID-19. Meanwhile, a repurposing screen by Aldeyra could yield...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

...NGF - Nerve growth factor p53 (TP53) PRG4 (HAPO) - Proteoglycan 4 PTGES (mPGES-1) - Microsomal prostaglandin E synthase-1...
BioCentury | Feb 15, 2019
Company News

India's Glenmark spinning out innovative assets into U.S. unit

...chronic obstructive pulmonary disease (COPD). The pain management programs are GRC 27864, an inhibitor of PTGES...
...2; OX40 (TNFRSF4; CD134) - Tumor necrosis factor receptor superfamily member 4; PTGES (mPGES-1) - Microsomal prostaglandin E synthase-1...
...Pharmaceuticals Ltd. CD3 CD38 Epidermal growth factor receptor (EGFR) (ErbB1) (HER1) Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) Microsomal prostaglandin E synthase-1 (PTGES) (mPGES-1) Transient...
BioCentury | Feb 14, 2019
Company News

India's Glenmark spinning out innovative assets into U.S. unit

...chronic obstructive pulmonary disease (COPD). The pain management programs are GRC 27864, an inhibitor of PTGES...
...2; OX40 (TNFRSF4; CD134) - Tumor necrosis factor receptor superfamily member 4; PTGES (mPGES-1) - Microsomal prostaglandin E synthase-1...
...Pharmaceuticals Ltd. CD3 CD38 Epidermal growth factor receptor (EGFR) (ErbB1) (HER1) Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) Microsomal prostaglandin E synthase-1 (PTGES) (mPGES-1) Transient...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
BioCentury | Feb 18, 2016
Product R&D

Crossing paths

...regulator of macrophage activation Phase II Global Neurotech (GNT) Pharma Co. Ltd. AAD-2004 Microsomal prostaglandin E synthase-1 (PTGES; mPGES-1...
BioCentury | Jan 28, 2016
Distillery Therapeutics

Therapeutics: Microsomal prostaglandin E synthase-1 (PTGES; mPGES-1); prostaglandin E2 (PGE2)

...Neurology INDICATION: Pain Cell culture, human blood and guinea pig studies identified PTGES inhibitors that could...
...arthritis-related pain. In in vitro enzymatic activity assays, two compounds based on different scaffolds inhibited PTGES...
...27864 , a PTGES inhibitor, in preclinical testing to treat autoimmune disease. TARGET/MARKER/PATHWAY: Microsomal prostaglandin E synthase-1 (PTGES; mPGES-1...
BioCentury | May 8, 2014
Distillery Therapeutics

Indication: Infectious disease

...inhibiting PTGES could help treat influenza A virus infection. In mice infected with influenza A, Ptges...
...nodes compared with no alteration. In mice lacking T and B cells, adoptive transfer of Ptges-deficient...
...interferon response than adoptive transfer of infected wild-type macrophages. In wild-type mice, an inhibitor of PTGES...
Items per page:
1 - 10 of 23